Get the Stockscreener App
88.24
0.35%
-0.31
After Hours:
88.24
Celcuity Inc stock is traded at $88.24, with a volume of 1.11M.
It is down -0.35% in the last 24 hours and down -35.91% over the past month.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
See More
Previous Close:
$88.55
Open:
$89.97
24h Volume:
1.11M
Relative Volume:
0.93
Market Cap:
$4.30B
Revenue:
-
Net Income/Loss:
$-192.89M
P/E Ratio:
-22.64
EPS:
-3.8976
Net Cash Flow:
$-172.97M
1W Performance:
+0.93%
1M Performance:
-35.91%
6M Performance:
-13.64%
1Y Performance:
+628.65%
1-Day Range:
$86.53
$90.61
1-Week Range:
$85.54
$95.97
52-Week Range:
$11.28
$151.02
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
88.24 | 4.32B | 0 | -192.89M | -172.97M | -3.8976 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Dec-12-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Nov-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-22-25 | Initiated | Guggenheim | Buy |
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Trading the Move, Not the Narrative: (CELC) Edition - Stock Traders Daily
CELC News | CELCUITY INC (NASDAQ:CELC) - ChartMill
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
Guggenheim Initiates Coverage of Celcuity (CELC) with Buy Recommendation - MSN
CELC stock records worst day ever after late-stage breast cancer trial results — what’s driving the selloff? - MSN
ACT CAPITAL MANAGEMENT, LLC's Celcuity Inc(CELC) Holding History - GuruFocus
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
Celcuity raises $500M in upsized 0.25% convertible notes sale - MSN
TD Asset Management Inc Has $9.73 Million Stake in Celcuity, Inc. $CELC - MarketBeat
CELC6416934 Bond Coupon Analysis — Rate & Payments - TradingView
Celcuity shares fall despite strong phase 3 breast cancer trial data (CELC) - MSN
Celcuity Refinances Debt with New Convertible Notes Offering - TipRanks
Celcuity Raises $575 Million in 0.25% Convertible Notes Due 2032; Net Proceeds $557 Million - TradingView
Geode Capital Management LLC Purchases 64,213 Shares of Celcuity, Inc. $CELC - MarketBeat
BNP Paribas Financial Markets Sells 36,648 Shares of Celcuity, Inc. $CELC - MarketBeat
CELC6416934 Bond Price and Chart — FINRA:CELC6416934 - TradingView
Preferred dividends of Celcuity Inc. – HAM:7VR - TradingView
Does Celcuity’s (CELC) Low‑Coupon Convertibles Hint at Strategic Caution or Commercial Ambition? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
CELC6416934 Bond Analysis — Key Metrics - TradingView
Cash from investing activities of Celcuity Inc. – HAM:7VR - TradingView
Operating expenses (excl. COGS) of Celcuity Inc. – HAM:7VR - TradingView
After tax other income/expense of Celcuity Inc. – XETR:7VR - TradingView
Celcuity Inc. Cash Flow – LSX:A2JAAX - TradingView
ETFs Investing in Celcuity Inc. Stocks - TradingView
Non-operating income (total) of Celcuity Inc. – DUS:7VR - TradingView
Long term debt to total assets ratio of Celcuity Inc. – DUS:7VR - TradingView
Asset turnover of Celcuity Inc. – DUS:7VR - TradingView
Long term debt to total assets ratio of Celcuity Inc. – LS:A2JAAX - TradingView
Price to book ratio of Celcuity Inc. – DUS:7VR - TradingView
A2JAAX Stock Price and Chart — LS:A2JAAX - TradingView
Celcuity Inc. Balance Sheet – DUS:7VR - TradingView
Celcuity Inc. Statistics – DUS:7VR - TradingView
Celcuity Inc. Financial Statements – DUS:7VR - TradingView
Net income of Celcuity Inc. – DUS:7VR - TradingView
How Celcuity CEO Brian Sullivan Is Framing Cancer Drug Development Around Hope for Patients - SurvivorNet
Celcuity Inc. Financial Statements – LS:A2JAAX - TradingView
HC Wainwright Has Negative Estimate for Celcuity Q3 Earnings - MarketBeat
Celcuity falls after detailed late-stage trial data for breast cancer drug - MSN
Celcuity Expands VIKTORIA-2 Trial As Shares Trade Below Targets - Sahm
Celcuity director Richard Buller sells $1.26 million in stock - Investing.com
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and Gedatolisib EfficacySlideshow (NASDAQ:CELC) 2026-06-04 - Seeking Alpha
Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering - Yahoo Finance
Celcuity (NASDAQ:CELC) Sees Strong Trading VolumeShould You Buy? - MarketBeat
A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $145 to $171 - Moomoo
Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients - Insider Monkey
H.C. Wainwright cuts Celcuity stock price target on revised penetration estimates - Investing.com UK
Wells Fargo cuts Celcuity stock price target on modest trial data - Investing.com UK
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):